A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 948 participants.
Also called NCT07889648
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 948 participants
- Sponsor
- Registry
-
NCT07889648 -
2026-526948-13-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07889648. Randomized; no masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2029-04-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
- Acronym
- ENI-SPIRE-2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Combination product)
- Enicepatide
- Intervention (Combination product)
- Tirzepatide
- Lead sponsor
- Hoffmann-La Roche
- Collaborator
- Chugai Pharmaceutical
Record details
- Record id
cardio:ct-nct07889648- Content hash
e468e4578ef5b97e609d3e47cc03b881750b2b312ccab4bba53c33bc34b3c27e